Loading
Life sciences · Journal article
Cumhuriyet Science Journal · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Colorectal cancer remains a leading cause of cancer-related mortality worldwide, with chemoresistance representing a major therapeutic challenge. The transforming growth factor-beta (TGF-β) signaling pathway contributes to tumor progression and treatment resistance, making it a promising target for combination therapy. This study investigated whether the dual TGF-β receptor I/II inhibitor LY2109761 enhances the cytotoxic effects of 5-fluorouracil (5-FU) in colorectal cancer cells while assessing its impact on immune cell viability. Cell viability was determined by MTT assay following treatment with 5-FU and LY2109761, alone or in combination, in HCT 116 colorectal cancer cells. Preliminary Bliss independence analysis indicated a localized positive interaction at selected concentrations; however, the limited concentration matrix precludes a definitive conclusion regarding pharmacological synergy. Exploratory ELISA analyses revealed non-significant changes in TGF-β and TGF-βR2 levels following treatment. Because downstream TGF-β signaling was not directly assessed, these findings should not be interpreted as mechanistic evidence of pathway inhibition. Nevertheless, LY2109761 enhanced the cytotoxic activity of 5-FU under selected concentration conditions and did not markedly increase apoptotic death in PBMCs, supporting further mechanistic and preclinical investigation of this proof-of-concept combination strategy.